RecruitingPhase 4NCT06449833

Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD

Studying NON RARE IN EUROPE: Non-alcoholic fatty liver disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zhujiang Hospital
Principal Investigator
Hong Chen, MD
Zhujiang Hospital
Intervention
Henagliflozein and Metformin(drug)
Enrollment
100 target
Eligibility
18-75 years · All sexes
Timeline
20242026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06449833 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease

← Back to all trials